Henry Schein Balances Strong Growth With Margin Pressure
Henry Schein ((HSIC)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Henry Schein’s latest earnings call struck a tone of cautious optimism, with management emphasizing strong top‑line momentum, accelerating specialty and technology businesses, and healthy cash generation. At the same time, executives acknowledged margin pressure from product mix, looming restructuring costs, softer medical demand, and tariff and macro risks, framing 2026 as a transition year with back‑half upside.
Robust Sales Growth Caps Best Quarter in Years
Henry Schein reported Q4 global sales of $3.4 billion, up 7.7% year over year, or 5.8% in constant currency, helped by a 1.9% FX tailwind and 0.9% contribution from acquisitions. Management highlighted that this was the strongest quarterly sales growth in 15 quarters and said momentum carried into January 2026, underscoring solid demand across core markets.
Equipment and International Segments Lead the Charge
Dental equipment was a standout, with U.S. sales advancing 10.6% and international dental equipment up 13.9%, or 7.5% in constant currency. Digital equipment unit growth was positive across 2D and 3D imaging, mills, 3D printers, and intraoral scanners, reinforcing the company’s positioning in higher‑tech, procedure‑enabling tools.
Specialty Products Deliver Double‑Digit Gains
Global Specialty Products continued to accelerate, with sales climbing 14.6%, or 11.1% in constant currency, driven by implants and biomaterials. Value implants grew at a double‑digit pace and premium implants in the mid‑single digits, with brands such as BioHorizons Camlog in Germany, SIN in Brazil, and Biotech in France among notable contributors.
Technology and SaaS Show Structural Momentum
The Global Technology Group posted 8.4% sales growth, or 7.6% in constant currency, powered by expanding cloud adoption and recurring revenue. Cloud‑based customers rose more than 20% year over year, with over 11,000 Dentrix Ascend subscribers, while new AI initiatives with AWS and workflow tools such as Voice Notes and ImageVerify deepened the platform’s value.
Profits Improve Despite Flat Operating Margin
Quarterly profitability improved on both a GAAP and non‑GAAP basis, with GAAP net income rising to $101 million, or $0.85 per diluted share, from $94 million, or $0.74, a year earlier. Non‑GAAP net income reached $160 million, or $1.34 per share, versus $149 million, or $1.19, while the non‑GAAP operating margin held roughly flat at 7.42% despite pressure on gross margins.
Cash Flow Strengthens and Buybacks Continue
Operating cash flow surged to $381 million in Q4 from $204 million in the prior‑year period, reflecting significant working‑capital improvements. Henry Schein repurchased about 2.8 million shares during 2025 for $200 million at an average price of $71.10, and the board left approximately $780 million of authorization available, underscoring continued commitment to shareholder returns.
Value‑Creation Plan Targets Operating Income Upside
Management reiterated its value‑creation roadmap, targeting more than $200 million of operating‑income improvement over the next few years through efficiency and growth initiatives. By 2026, the company expects to be running at an annualized operating‑income benefit exceeding $125 million, which it sees as a key lever to support earnings growth beyond modest top‑line expansion.
Strategic Wins Bolster Commercial Platform
Henry Schein highlighted several strategic and commercial wins, including the rollout of its global e‑commerce platform henryschein.com, with U.S. dental and Canadian launches slated for early 2026. New exclusive distribution deals, such as Novartis’ Curaden product and CytoChip’s CytoCBC point‑of‑care CBC system, plus expanded data‑driven marketing, aim to deepen customer engagement and supplier ties.
Mix‑Driven Gross Margin Pressure Persists
Despite higher gross profit dollars, overall gross margins contracted, largely because of product‑mix shifts toward lower‑margin categories such as value implants. Management framed this as an intentional trade‑off, prioritizing volume and market share in fast‑growing segments, but acknowledged that it constrains the gross‑margin percentage even as the franchise expands.
Restructuring Weighs on GAAP Margins
Full‑year 2025 GAAP operating margin dipped to 4.76%, down 10 basis points year over year, as restructuring expenses tied to an August 2024 program totaled about $105 million, including $23 million in the fourth quarter. Given ongoing restructuring and value‑creation investments, Henry Schein declined to issue GAAP guidance for 2026, signaling that transformation costs remain difficult to quantify.
Medical Business Faces Post‑Pandemic Headwinds
In the U.S. medical segment, the company reported lower demand in respiratory products as COVID‑era testing volumes and general respiratory visits normalized, a weakness that has continued into the first quarter of 2026. Management suggested that while the broader medical franchise remains stable, the fading tailwind from respiratory categories is a drag on growth comparisons.
One‑Time Remeasurement Gains Set to Fade
Executives cautioned that remeasurement gains related to M&A and portfolio adjustments, which boosted results in 2025, are expected to be lower in 2026. That drop in one‑time benefits will reduce a source of EPS upside, making underlying operating improvements and cost efficiencies more important to sustain earnings momentum.
Pricing Pressure in Select Technology and Supply Lines
Average selling prices for intraoral scanners have been edging down as lower‑priced competitors enter the market, softening price realization even amid healthy unit growth. Some other categories, such as gloves historically, have also faced pricing pressure, and while private‑label expansion supports margins, overall pricing dynamics across the portfolio remain mixed.
Transition Year Brings Near‑Term Lumpiness
Management warned that 2026 will feature some quarter‑to‑quarter lumpiness as value‑creation initiatives ramp and upfront implementation costs flow through the P&L. Benefits from these efforts are expected to be concentrated in the back half of the year, leaving early 2026 as a potential near‑term headwind before savings and efficiencies are fully realized.
Tariffs and Macro Uncertainty Remain Key External Risks
Henry Schein flagged tariffs and macroeconomic volatility as important external risks, especially in international markets, with recent trade rulings adding to uncertainty. The company plans to mitigate tariff impacts through alternative sourcing and pass‑through pricing where possible, but acknowledged that these factors could pressure margins and growth if conditions worsen.
Guidance Signals Modest Growth and Back‑Half Earnings Bias
For 2026, Henry Schein guided to sales growth of 3% to 5% versus 2025 and non‑GAAP diluted EPS of $5.23 to $5.37, implying roughly 5% to 8% earnings growth on a non‑GAAP basis. Adjusted EBITDA is expected to grow in the mid‑single digits, with assumptions of stable dental and medical end markets, FX roughly in line with current levels, manageable tariffs, and lower remeasurement gains, while earnings are projected to be weighted to the second half.
Henry Schein’s earnings call painted a picture of a company leaning on strong specialty, equipment, and tech franchises to offset margin and macro pressures as it invests in a value‑creation program. For investors, the story is one of steady, mid‑single‑digit growth and improving cash returns, tempered by restructuring noise and external risks that make execution in 2026 particularly important.
